GLP1R and obesity due to melanocortin 4 receptor deficiency: In a Phase II trial, individuals with T2DM and who were overweight or affected by obesity treated with the dual GLP‐1R/GCGR agonist cotadutide (MEDI0382) achieved significant lowering of glucose levels and bodyweight loss compared with patients receiving placebo over 41 days (p < 0.0001 and p = 0.0008, respectively).122